MBX Biosciences Inc [MBX] stock is trading at $25.57, up 3.35%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MBX shares have gain 16.44% over the last week, with a monthly amount glided 61.22%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Truist started tracking the stock with Buy rating on October 15, 2025, and set its price target to $50. Mizuho started tracking the stock assigning a Outperform rating and suggested a price target of $38 on August 05, 2025. Oppenheimer initiated its recommendation with a Outperform and recommended $38 as its price target on July 16, 2025. Citizens JMP started tracking with a Mkt Outperform rating for this stock on April 10, 2025, and assigned it a price target of $38. In a note dated October 08, 2024, Stifel initiated an Buy rating and provided a target price of $40 on this stock.
MBX Biosciences Inc [MBX] stock has fluctuated between $4.81 and $26.47 over the past year. Currently, Wall Street analysts expect the stock to reach $38 within the next 12 months. MBX Biosciences Inc [NASDAQ: MBX] shares were valued at $25.57 at the most recent close of the market. An investor can expect a potential return of 48.61% based on the average MBX price forecast.
Analyzing the MBX fundamentals
Gross Profit Margin for this corporation currently stands at -0.3% with Operating Profit Margin at -409.32%, Pretax Profit Margin comes in at -362.59%, and Net Profit Margin reading is -362.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.29 and Total Capital is -0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.08 points at the first support level, and at 20.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.88, and for the 2nd resistance point, it is at 28.18.
Ratios To Look Out For
For context, MBX Biosciences Inc’s Current Ratio is 32.95. As well, the Quick Ratio is 32.95, while the Cash Ratio is 18.5.
Transactions by insiders
Recent insider trading involved Hawryluk P. Kent, President & CEO, that happened on Oct 20 ’25 when 20000.0 shares were purchased. Director, Hoerter Steven L. completed a deal on Oct 17 ’25 to buy 20000.0 shares. Meanwhile, Director Heron Patrick J bought 0.67 million shares on Sep 26 ’25.
